Tag: B-cell malignancy options

Home / B-cell malignancy options

Categories

Zanubrutinib is approved by the USFDA for relapsed or refractory follicular lymphoma

March 2024: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) in combination with obinutuzumab has been granted accelerated approval by the Food and Drug Administration for the treatment of relapsed or refra...
b-cell-malignancy-options

Scan the code